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Summary FCE 24157 (chemically (i-(1-methyl-4-(1-methyl-4--[1-methyl-4-(4-N,N-bis(2-chloroethyl) amino-
benzene-l-carboxy-amido) pyrrole-2-carboxiamido]pyrrole-2-carboxyamido)pyrrole-2-carboxyamido)) propion-
amidine, hydrochloride) is a distamycin A (Dista A) derivative bearing a benzoyl mustard moiety instead of
the formyl group at the N-terminal.
Contrary to Dista A, FCE 24517 has been found to display potent cytotoxic activity on human and murine
tumour cell lines. The compound maintains activity on melphalan (L-PAM)-resistant cells, whereas cross-
resistance is observed on doxorubicin-(DX)-resistant cells.
In vivo, FCE 24517 was found to possess evident antineoplastic activity on a series of murine transplanted
solid tumours and human tumour xenografts. The following neoplasms were in fact found to be sensitive to
FCE 24517 treatment: M14 human melanoma xenograft, N592 human small cell lung carcinoma, MTV
murine mammary carcinoma, Colon 38 murine carcinoma, P02 murine pancreatic carcinoma and M5076
murine reticulosarcoma. Lower effectiveness was observed against the murine P388 and Gross leukaemia,
Lewis lung murine carcinoma, LoVo human colon carcinoma xenografts and A459 human lung adenocar-
cinoma. Against the murine L1210 leukaemia, FCE 24517 displayed a clear activity only when the tumour was
transplanted i.p. and treatment was given i.p., whereas only marginal activity was seen against this leukaemia
if transplanted i.v. and the drug was given i.v. As true also in vitro, FCE 24517 was effective against i.p.
implanted L1210 leukaemia resistant to L-PAM. The mode(s) of action of this new compound is under active
investigation.
Distamycin A (Dista A, Figure 1) is an antiviral antibiotic
originally isolated from cultures of Streptomyces distallycus
(Di Marco et al., 1962), whose structure was characterised in
our laboratories (Arcamone et al., 1964). In experimental
models, Dista A has shown only minimal cytotoxic and
antitumour activity whereas it revealed a potent antiviral
activity especially against Herpes simplex (Casazza et al.,
1965). Dista A has been demonstrated to inhibit DNA-
polymerase, secondary to a strong and selective affinity for
T:A-rich sequences of B DNA (Zimmer & Wahnert, 1986).
In the aim of obtaining anticancer agents with potentially
novel molecular target(s) and mechanism(s) of action, a
number of Dista A derivatives bearing different alkylating
reactive moieties were synthesised. The synthesis, DNA-
binding properties and preliminary information on the
biological activity of a number of selected derivatives have
been published (Arcamone et al., 1989).
In this report we describe results obtained in the charac-
terisation of the antineoplastic activity in experimental
models of FCE 24517 (Figure 1), a chemical that differs from
Dista A in bearing a benzoyl mustard moiety instead of the
formyl group at the N-terminal position.
Materials and methods
Compounds
FCE 24517, distamycin A (Dista A) and doxorubicin (DX)
were dissolved in sterile water immediately before use and the
concentrations checked spectrophotometrically following
dilution of stock solutions in ethanol. Dista A A max at
305 nm, El % = 674 (in ethanol), FCE 24517 A max at
314 nm, El% = 744.09 (in ethanol), DX A max at 496,
El % = 200 (in water). Melphalan (L-PAM) was freshly dis-
solved in 1 N HCI at a concentration of 20 mgml-' and
further diluted in culture.
Cell cultures
L1210 and L1210/L-PAM murine leukaemia cells were
routinely derived from leukaemia-bearing mice and main-
tained in RPMI 1640 medium (Gibco 074-1800) supple-
mented with 0.01 and 0.05 mM P-mercaptoethanol,
respectively. LoVo (Drewinko et al., 1976) and LoVo/DX
(Grandi et al., 1986) human colon carcinoma cells were
maintained in Ham's F12 medium (Gibco 074-1700). All
culture mediums were supplemented with 10% foetal calf
serum (Flow), 1% of a glutamine solution (200 mM), penicil-
lin (100 IUml-1), streptomycin (100 tgml-') and kanamycin
(1001tigml-'). Cells were maintained at 37C in humidified
atmosphere of 5% CO2 and passaged twice weekly.
Evaluation ofin vitro cytotoxicity
A colony inhibition test was employed in the case of LoVo
and LoVo/DX cells: a total of 600 cells in 2 ml medium were
seeded in 60 mm tissue culture dishes (Falcon) 24h before
treatment; after 4 h exposure to drugs, dishes were washed
with saline and fresh growth medium added. Surviving col-
H NH NH
0 HN
3 CH3 H
D ICSHT A " Y C I N
D I ST A NY C I N
CH3 CH3
F C E 2 4 5 1 7
Figure 1 Chemical structures of distamycin A and FCE 24517.
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onies were counted after 7 days incubation. A growth inhibi-
tion test was performed on L1210 and L1210/L-PAM cells.
Cells (3.I0O ml-') were treated with drugs for 4 h, and
resuspended in fresh medium. After 48 h recovery, cytotoxi-
city was determined by counting cells in a Coulter Counter
(Kontron ZM). For both methods, data were expressed as
percentage of controls, and the 50% inhibiting concentration
(IC50) was calculated on dose-response curves. All
experiments were run in triplicate and values reported repre-
sent the average of at least three different experiments.
Animals
Inbred DBA2, C57BL/6, C3H/HeN, CD2F1, B6D2F1 mice
of both sexes were used. In experiments with human tumour
xenografts, adult male Swiss/nu/nu mice were employed. All
animals were supplied by Charles River Italy (Calco, Italy).
The animals were 2 to 3 months old and were kept under
standard laboratory conditions. Nude mice were maintained
in cages with paper filter covers; food and bedding were
sterilised and water was acidified (pH 2.5-3).
Evaluation ofantineoplastic activity
The L1210 murine leukaemia and its L-PAM resistant sub-
line (L1210/L-PAM, originally obtained from the N.C.I.,
Betheseda USA) were maintained by weekly i.p. passages of
106 cells in DBA2 mice; in the case of L1210/L-PAM, mice
were treated weekly with 7.5 mg kg' i.p. of L-PAM. For
experimental studies, i.p. or i.v. inocula of 105 cells in CD2F1
mice were used. The P388 murine leukaemia was maintained
by weekly i.p. passages of 106 cells in DBA2 mice; for
experiments, 106 cells/mouse were transplanted i.v. in CD2F1
mice. The Gross murine leukaemia was maintained by serial
i.v. passages in syngeneic C3H/HeN mice of a spleen and
peripheral lymph nodes homogenate from leukaemic mice;
experiments were carried out in animals of the same strain,
using i.v. inocula of 2 x 106 cells/mouse.
The Lewis lung carcinoma (105 cells/mouse) and M5076
murine reticulosarcoma (5 x 105 cells/mouse) were trans-
planted i.m. in syngeneic C57BL/6 mice to evaluate drug
effects on primary tumour growth. For the evaluation of
antimetastatic activity, 105 M5076 cells were injected i.v. in
the tail vein of mice. The murine mammary carcinoma
(MTV), from a third generation spontaneous tumour, was
inoculated s.c. (2 x 107 cells) in syngeneic C3H/HeN females
(Di Marco et al., 1972). The P02 murine pancreatic car-
cinoma (Corbett et al., 1984), and the MXT murine fibrosar-
coma (Zaccheo et al., 1986) were transplanted s.c. in
compatible B6D2F1 mice, whereas the murine colon 38
tumour was transplanted s.c. in syngeneic C57BL/6 mice,
using in all cases inocula of 15-20 mg of tumor brei. The
human small cell lung carcinoma N592, A549 lung adenocar-
cinoma (both originally obtained from the ATCC),
melanoma M14 (Natali et al., 1983), and LoVo colon car-
cinoma (Drewinko et al., 1976) were transplanted s.c. in
athymic mice using 15-20mg of tumor brei.
In experiments in leukaemia models, drug activity was
evaluated in terms of per cent increase in median survival
time in comparison to untreated controls (T/C %). In
experiments with solid tumours, primary tumour growth was
assessed by caliper measurement, and tumour weight was
estimated (Geran et al., 1972). Toxicity was evaluated on the
basis of gross autopsy findings, as well as on the basis of
reduction in survival time below that of untreated controls.
Results
In vitro cytotoxic activity
Table I shows data obtained testing the in vitro anti-
proliferative activity of FCE 24517 on parental L1210 and
LoVo cells and their L-PAM and DX-resistant sublines. On
both parental L1210 and LoVo cells, FCE 24517 was clearly
cytotoxic, with IC50 values in the range of 0.14 to
0.6 lag ml -, whereas the parent compound Dista A was only
active at higher concentrations. On L12lO/L-PAM cells the
cytotoxic activity of FCE 24517 was comparable to that seen
on parental cells, thus indicating a lack of cross-resistance
with classical alkylating agents such as L-PAM. Conversely,
cross-resistance was observed on LoVo/DX, a subline
exhibiting the 'classical multidrug resistance' (mdr) phenotype
(Ballinari et al., 1988).
Antineoplastic activity
Representative results obtained investigating the activity of
FCE 24517 against transplantable murine leukaemias are
summarised in Table II. Against the i.p. transplanted L1210
and L1210/L-PAM leukaemias, the administration of FCE
24517 at the maximally tolerated single dose of
3.125 mg kg-' i.p. was associated with T/C% values of 175
and 144, respectively, the latter result thus confirming the
lack of cross-resistance with L-PAM already observed in
vitro. Conversely, when FCE 24517 was tested against the i.v.
transplanted L1210 and L1210/L-PAM leukaemias, it was
only marginally active (T/C% of 125 and 133) when given as
a single (3.125 mg kg-') i.v. injection. In the i.v. L1210
leukaemia model, a number of other treatment schedules
with repeated drug administrations at different time intervals
were also tested, but in all cases only marginal efficacy was
observed (data not shown).
In the model of the i.v. transplanted P388 leukaemia,
single i.v. injections of FCE 24517 at the optimal dose of
3.125 mg kg-' were only marginally effective, with T/C%
value of 125. On the disseminated Gross leukaemia model,
the compound showed a better activity with T/C% value of
the order of 154 at the same dose.
Results obtained testing the antitumour activity of FCE
24517 against a panel of solid murine neoplasms are reported
in Table III. Against the advanced MTV murine mammary
carcinoma the compound was clearly active, giving 100%
tumour inhibition at the optimal dose of 1.56mg kg-'.
Antitumour effect was also observed against the' advanced
MXT fibrosarcoma, P02 pancreatic carcinoma and Colon 38
carcinoma, as indicated by tumour inhibition values ranging
between 66 and 75% at the maximally tolerated repeated
doses of 1.56mgkg-'.
When tested against the i.m. implanted M5076 reticulosar-
coma, a significant antitumour activity in terms of reduction
of primary tumour weight was observed at the optimal dose
of 1.56 mg kg-' x 3, a treatment that was also associated
with an approximately 50% increase in survival time. A clear
Table I Cytotoxic activity of FCE 24517, Dista A, L-PAM and DX
IC50a (figml-') IC50* (jAgml-])
Compound L1210 L1210/L-PAM R.L* LoVo LoVo/DX R.I.*
FCE 24517 0.607 0.24b 0.376 0.21 0.62 0.137 0.07 4.8 ± 0.75 35
Dista A 207 68 175 54 0.85 976 265 1255 ± 12.1 1.3
L-PAM 0.621 ±0.103 3.617 0.8 5.8 1.1 ±0.29 1.13 ± 0.4 1.03
DX 0.075 ± 0.023 0.088 ± 0.01 1.2 0.076 ± 0.02 5.1 ± 0.97 66
'R.I.: resistance index IC50 on resistant cells
IC50 on sensitive cells
bMean of at least three experiments, ± standard deviation.ANTITUMOUR ACTIVITY OF THE NEW DISTAMYCIN 1049
Table II Antileukaemic activity of FCE 24517
Tumour and Route and
site of treatment Dose TICa Toxic deaths
implant schedule (mgkg-I) % Total no. of mice
Gross i.v. i.v. + 1 3.125 154 0/12
4.69 143 1/10
P388 i.v. i.v. + 1 3.125 125 0.10
4.68 100 8/10
L1210 i.p. i.p. + 1 3.125 175 0/10
4.06 100 6/10
L1210/L-PAM i.p. i.p. + 1 3.125 144 0/18
4.06 172 1/8
L1210 i.v. i.v. + 1 3.125 125 0/18
4.68 150 2/9
L1210/L-PAM i.v. i.v. + 1 3.125 133 0/10
4.68 133 2/10
aT/C%: median survival time.
Table III Antineoplastic activity of FCE 24517 on murine solid tumours
Tumour and Route and
site of treatment Dose T.I. rica Toxic deaths
implant schedule (mgkg-' day-') % % Total no. of mice
MTV mammary s.c. i.v. + 22, 29, 36, 43 1.56 100 132 0/9
2.02 nd 88 9/9
MXT fibrosarcoma s.c. i.v. + 3, 7, 11 1.56 66 103 1/10
3.12 78 75 10/10
P02 pancreatic ca s.c. i.v. + 3, 7, 11 1.56 75 102 0/20
2.34 89 67 10/10
Colon 38 s.c. i.v. + 7, 14, 21, 28 1.56 69 98 1/8
2.02 70 104 5/8
M5076 reticulosarcoma i.m. i.v. + 3, 7, 11 1.56 92 147 0/10
3.12 100 150 10/10
M5076 reticulosarcoma i.v. i.v. + 1, 5, 9 1.56 - 153 0/30
2.02 - 170 3/30
Lewis lung ca i.m. i.v. +3, 7, 11 1.56 41 104 0/10
2 51 77 7/10
aT.I.%: percentage of tumour growth inhibition, determined 1 week after the last treatment. bT/C%: median survival
time.
activity in prolonging the survival time (T/C% values of
156-170%) was moreover observed in mice bearing artificial
liver metastasis induced by the i.v. injection of M5076 cells.
In the Lewis lung carcinoma model, a 40% inhibition of
primary tumour growth was obtained at the maximally
tolerated repeated dose of 1.56mgkg-' of the compound.
Representative data on the response of different human
tumour xenografts to FCE 24517 are shown in Table IV. It
can be seen that at the dose of 1 mg kg-' i.v. q4dx3, this
compound was active against the N592 human small cell
lung carcinoma and M14 melanoma, producing tumour
inhibition values of 95% and 86%, respectively. Lower
activity was seen when FCE 24517 was tested against the s.c.
transplanted LoVo human colon adenocarcinoma and A549
human lung adenocarcinoma lines, as revealed by tumour
growth inhibitions in the 40-50% range.
Discussion
The results presented in this report demonstrate that FCE
24517 possesses a clear and broad-spectrum antineoplastic
activity in experimental conditions, and thus that this com-
pound, a derivative of the antiviral agent Dista A bearing at
the N-terminal an alkylating benzoyl mustard moiety,
represents a novel chemical class of antitumoural agents.
The insertion of an alkylating moiety on the Dista A
skeleton confers to this molecule a potent antiproliferative
activity. In fact, FCE 24517 is significantly more cytotoxic
than its parent compound not only on L1210 and LoVo cells
(Table I) but also on several other murine and human cell
lines so far investigated (data not shown). Notwithstanding
its alkylating appendage, FCE 24517 was observed to have
an equivalent cytotoxic activity on parental and L-PAM-
resistant L1210 cells, this lack of cross-resistance being
confirmed in vivo on the same cell lines. Conversely, FCE
24517 was cross-resistant on LoVo/DX cells, a subline
exhibiting the classical mdr phenotype.
FCE 24517 showed a clear antineoplastic activity in vivo
against a variety of experimental tumours of both murine
and human origin, although the best activities were obtained
in most cases near the maximum tolerated doses, and the
degree of therapeutic effectiveness observed varied in
different models. Treatment with FCE 24517 was in fact
effective against the murine MTV mammary, P02 pancreatic
and Colon 38 carcinomas, M5076 reticulosarcoma and MXT
fibrosarcoma as well as on xenografts of the human M14
melanoma and N592 small cell lung carcinoma as indicated
by over 70-80% inhibition of tumour growth. Lower
effectiveness was observed on the murine Lewis lung car-
cinoma, human A549 lung adenocarcinoma and LoVo colon
adenocarcinoma with primary tumour growth inhibition in
the 40-50% range. It should however be noted that no
systematic attempt was made in this study to identify the
optimal in vivo treatment schedules for improving the
therapeutic index or enlarging the spectrum of activity. FCE
24517 was additionally active in the murine Gross leukaemia
model and, if given i.p., against the L1210 leukaemia and its
L-PAM-resistant subline. In contrast, systemic treatment
with this agent was associated with only marginal activity
against i.v.-transplanted L1210 and P388 leukaemias despite
the use of doses active in the Gross leukaemia model.
The basis for this low antileukaemic effectiveness remains
hypothetical and more than one determinant may be
involved. In this connection, it is also worth noting that
preliminary results indicate marginal activity in the P388 and
L1210 models also employing repeated FCE 24517 admini-
strations at doses and schedules clearly active in solid
tumours (data not shown), a finding unexpected in view of
the well known fact that these leukaemias have shown
greater responsiveness then solid experimental neoplasms to
the majority of known cancer chemotherapeutics (Staquet et1050 G. PEZZONI et al.
Table IV Antineoplastic activity of FCE 24517 against human tumour xenografts
Tumour and Route and
site of treatment Dose T.ILa Toxic deaths
implant schedule (mgkg-' day-') % Total no. of mice
N 592 small cell lung s.c. i.v. + q4d x 3 1 95 0/8
carcinoma 1.56 94 1/8
M 14 melanoma s.c. i.v. + q4d x 3 1 86 0/7
A 549 lung s.c. i.v. + q4d x 3 0.8 45 0/7
adenocarcinoma 1.2 56 2/7
LoVo colon s.c. i.v. + q4d x 3 1 54 0/7
adenocarcinoma 1.56 43 5/7
aT.I.%: percentage of tumour growth inhibition, determined 1 week after the last treatment.
al., 1983; Grindey, 1990). Although data so far available
would appear to suggest this molecule possesses an unusual
pattern of antineoplastic activity with limited antileukaemic
effectiveness and clear, broad spectrum efficacy in experi-
mental solid tumours, results in other leukaemia-lymphoma
models are however needed before a more firm conclusion on
this differential activity is advanced. Should such
confirmations be obtained, the indication that FCE 24517
represents the lead of a novel class of cancer chemothera-
peutics would be reinforced.
The cellular and molecular mechanisms at the basis of the
antitumour activity of FCE 24517 are only partially resolved
and a matter of active ongoing investigation. In a recent
report (Broggini et al., 1991), evidence is presented that in
cultured L1210 cells this compound does not act as an
inhibitor of DNA, RNA and protein synthesis, nor as an
antimitotic agent, and to block cells in G2. In the same cell
type, exposure to cytocidal concentrations of FCE 24517 was
not associated with DNA strand breaks, interstrand cross-
links or DNA-protein cross-links. Dista A has been shown to
bind selectively to T:A-rich sequences in B DNA and it has
been reported that binding of this molecule to DNA minor
groove induces conformational changes in neighbouring
DNA which may affect protein-DNA interactions (Kopka et
al., 1985).
Dista A has also recently been observed to inhibit the
binding of selected regulatory proteins to their T:A-rich
DNA sequences (Broggini et al., 1989). However FCE 24517
was found to be quantitatively comparable to Dista A in
both DNA binding in vitro and in inhibiting the binding of
regulatory proteins to T:A-rich regions, and both com-
pounds appear to have similar cellular uptake and retention
characteristics (Broggini et al., 1991). Since Dista A is essen-
tially inactive as an antitumour agent in vitro and in vivo even
at concentrations 100 times higher than those effective for the
derivative, it would appear that the alkylating benzoyl mus-
tard absent in Dista A and present in FCE 24517 is essential
in imparting an antiproliferative capacity to the latter.
Alkylation of DNA by FCE 24517 is however weak, and in
contrast to known nitrogen mustards, this compound does
not induce alkylation at guanine N7 but at selected adenines
(Broggini et al., 1991). The exact molecular mechanisms of
this molecule are however still a matter of speculation also in
consideration of the finding that this compound has addi-
tionally been found to display a very potent inhibitory
activity for DNA ligase in conditions not affecting DNA
polymerases (Montecucco et al., 1991).
In view of its mode of action that on the basis of available
evidence seems different from known cytototoxic agents, and
its broad spectrum of activity in experimental conditions,
FCE 24517 appears to be an interesting candidate for clinical
evaluation and phase I studies are already ongoing.
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